Experiences of Injectable Buprenorphine Users v3
Research type
Research Study
Full title
Examination of the Experiences and Self-determination of Injectable Buprenorphine users Compared to Oral Opioid Substitution Treatment Users.
IRAS ID
355052
Contact name
Matthew Cook
Contact email
Sponsor organisation
University of Southampton
Duration of Study in the UK
0 years, 9 months, 17 days
Research summary
The proposed investigation will look at service users who are taking Buvidal medication. Buvidal is a relatively new treatment which was approved in UK in 2019. It is a prolonged release Buprenorphine injection which is used as an Opioid Substitution Treatment (OST). OST is a drug treatment used to reduce or eliminate the use of opioids (predominantly heroin) in people who are dependant by replacing the heroin with an oral drug (a different opioid) such as methadone.
The focus of the proposed investigation is to investigate whether the change to an prolonged release treatment option has influenced the user’s perception of their self-determination, to assess whether the change in treatment option has an influence on the ability to refuse drugs in high risk situations, and to examine any difference in life experiences and change in wellbeing as a result of the change in treatment.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
26/YH/0018
Date of REC Opinion
11 May 2026
REC opinion
Further Information Favourable Opinion